FIRST PATIENT ENROLLED IN POINT THERAPEUTICS' NSCLC TRIAL

Point Therapeutics has enrolled the first patient in the company's second Phase III clinical trial, which will evaluate talabostat in combination with pemetrexed versus pemetrexed with placebo in patients with metastatic non-small cell lung cancer (NSCLC).

The trial is being conducted as part of a Phase III clinical program in NSCLC consisting of two randomized, double-blind, placebo-controlled trials in up to 800 patients at approximately 100 sites in North America. The first 400-patient trial, evaluating the combination of talabostat with docetaxel versus docetaxel and placebo, has already opened to enrollment.